OncoMatch/Clinical Trials/NCT05256641
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Is NCT05256641 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Acalabrutinib for diffuse large b-cell lymphoma.
Treatment: Acalabrutinib — This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Primary Central Nervous System Lymphoma
Biomarker criteria
Required: BCL2 rearrangement
Required: BCL6 rearrangement
Required: MYC rearrangement
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: autologous stem cell transplant
Patients undergoing autologous stem cell transplantation (ASCT)
Must have received: CAR-T cell therapy
any Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T-cell therapy product
Must have received: allogeneic hematopoietic cell transplantation
Patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for large B-cell lymphoma
Lab requirements
Blood counts
Absolute neutrophil count (ANC) > 500/uL; Platelets > 50,000/uL independent of transfusions; Hemoglobin > 8 g/dL independent of transfusions
Kidney function
Creatinine clearance >= 60 mL/min based on Cockcroft-Gault glomerular filtration rate (GFR) and serum creatinine (Cr) <= 1.8 mg/dL
Liver function
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3 x upper limit of normal (ULN); Total bilirubin <= 1.5 x ULN, unless directly attributable to Gilbert's syndrome
Cardiac function
Left ventricular ejection fraction >= 50%
Absolute neutrophil count (ANC) > 500/uL; Platelets > 50,000/uL independent of transfusions; Hemoglobin > 8 g/dL independent of transfusions; Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3 x upper limit of normal (ULN); Total bilirubin <= 1.5 x ULN, unless directly attributable to Gilbert's syndrome; Creatinine clearance >= 60 mL/min based on Cockcroft-Gault glomerular filtration rate (GFR) and serum creatinine (Cr) <= 1.8 mg/dL; Left ventricular ejection fraction >= 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA / Jonsson Comprehensive Cancer Center · Los Angeles, California
- University of California Davis Comprehensive Cancer Center · Sacramento, California
- University of Oklahoma · Oklahoma City, Oklahoma
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05256641 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received autologous stem cell transplant and CAR-T cell therapy.
Does this trial require BCL2?
Yes, BCL2 rearrangement is a required biomarker for enrollment.
Does this trial require BCL6?
Yes, BCL6 rearrangement is a required biomarker for enrollment.
Does this trial require MYC?
Yes, MYC rearrangement is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify